Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kevzara

- PMLiVE

WHO updates drug-resistant bacteria list to develop new treatments for AMR

The 2024 BPPL list includes 15 families of antibiotic-resistant bacteria

- PMLiVE

Governments continue proposed pandemic agreement progress ahead of World Health Assembly

The meeting focusing on ‘All for Health, Health for All’ takes place on 27 May to 7 June 2024

- PMLiVE

Takeda’s Qdenga becomes second dengue vaccine to receive WHO prequalification

Approximately half of the global population is at risk of mosquito-borne viral disease

- PMLiVE

AstraZeneca’s sipavibart shown to prevent COVID-19 in immunocompromised patients

Immunocompromised individuals account for about 25% of COVID-19 hospitalisations, intensive care unit admissions and deaths

- PMLiVE

WHO opens application period for 2025 Model Lists of Essential Medicines

The deadline to submit ahead of the 25th WHO Expert Committee meeting is 1 November 2024

- PMLiVE

WHO reveals ‘extensive’ worldwide overuse of antibiotics during COVID-19 pandemic

Findings from the report reveal factors that could have contributed to the spread of antimicrobial resistance

Biogen Idec building

Biogen’s tocilizumab biosimilar Tofidence recommended by CHMP to treat arthritis and COVID-19

The committee’s decision was supported by evidence demonstrating Tofidence’s similarity to Roche’s RoActemra

- PMLiVE

World Health Organization prequalifies simplified oral cholera vaccine Euvichol-S

The acute diarrhoeal illness was reported to affect around 473,000 people in 2022

- PMLiVE

World Health Organization launches AI-powered digital health assistant for public health

SARAH has been launched in alignment with World Health Day’s theme, ‘My Health, My Right’

- PMLiVE

FDA grants Invivyd’s Pemgarda emergency use authorisation for COVID-19 prevention

The long-acting monoclonal antibody is authorised for use in adults and adolescents

- PMLiVE

Gilead shares positive real-world data for COVID-19 treatment Veklury in hospitalised patients

Results were presented at the Conference on Retroviruses and Opportunistic Infections

- PMLiVE

Cambridge study reveals potential biomarker and target for long COVID treatments

The pro-inflammatory molecule, IFN-Y, persisted until symptoms improved in patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links